Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06694480 · ClinicalTrials.gov registry record · Phase 1

Study of FID-022 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Fulgent Pharma.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06694480 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Fulgent Pharma. The registered enrollment target is 24 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06694480, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Fulgent Pharma.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG FID-022

Study Locations (1)

California

  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-07-03
Est. Completion 2028-06-30
Phase Phase 1

Sponsor

Fulgent Pharma

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06694480

The ClinicalTrials.gov registry entry for NCT06694480 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The listed sponsor is Fulgent Pharma, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which FID-022 is the first listed.

NCT06694480 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06694480 about?

NCT06694480 is a clinical study titled "Study of FID-022 in Participants With Advanced Solid Tumors". The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.

What is the current status of trial NCT06694480?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-07-03. Estimated completion is 2028-06-30.

What conditions does trial NCT06694480 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06694480?

The interventions under investigation include: FID-022 (DRUG).

Who is sponsoring clinical trial NCT06694480?

This trial is sponsored by Fulgent Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06694480 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.